ArticleJMIR research protocols2026
Establish a PrEP (Pre-Exposure Prophylaxis) Epidemiology, Modeling, and Surveillance (PREMISE) System to Analyze Trends in PrEP Uptake and the Impact of PrEP Programs and Policies: Protocol for a Natural Experiment and Modeling Study in the United States.
Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Acting Injectable Cabotegravir Use and Persistence Over 2 Years.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPre-exposure prophylaxis (PrEP) is highly effective in preventing HIV transmission; yet, many people who would benefit from PrEP are not currently using it. Numerous programs and policies, including those provided under the US Ending the HIV Epidemic effort, have been implemented to increase PrEP use. Programs vary enormously, ranging from telemedicine PrEP support to electronic medical record prompts to social marketing and messaging campaigns. However, limited evidence exists regarding their relative impact on PrEP uptake.
objectiveThe aims of the PREMISE (PrEP Epidemiology, Modeling, and Surveillance) research program are to (1) provide context for PrEP scale-up in the United States, (2) assess the impact of different programs and policies on PrEP use, and (3) model the impact of PrEP-related programs and policies on population health.
methodsThe primary outcomes of PrEP use and PrEP-to-need ratios will be extracted from a national medical data aggregator database that represents a majority of PrEP users in the United States. These data will inform all proposed analyses of the project: the dataset will allow the exploration of longitudinal trends in PrEP use by modality as a cohort study, it will be the outcome data for assessing changes associated with particular PrEP programs and policies for quasi-experiments, and it will provide baseline information to inform modeling regarding future impacts of PrEP policies and programs. The implementation of policies will be assessed using legal coding at the state level, and the implementation of programs across health jurisdictions will be assessed using a jurisdiction survey conducted in collaboration with participating health departments. Guided by a legal implementation framework, we will use descriptive and regression analyses to contextualize PrEP scale-up and use quasi-experimental designs to inform causal assessments of the effect of programs and policies. Here, we provide, as preliminary data, our extraction of PrEP prescribing from the national dataset.
resultsThis research was funded in August 2024. We obtained the national PrEP database and started data cleaning in March 2025. From 2016 to 2024, there were 20,394,619 claims for medications that were FDA-approved for PrEP, and we determined 13,644,979 claims to be PrEP prescriptions, representing over 1 million PrEP users. For medical benefit claims, there were 34,525 procedure claims for PrEP medications, and we determined 22,910 procedure claims to be for PrEP, representing over 6000 PrEP users.
conclusionsTo optimally use HIV prevention resources, it is critical to understand the effects of different programs and policies. Over 1 million people have started PrEP, and tracking how this scale-up has occurred by PrEP modality and user groups will inform future HIV prevention efforts. By collaborating with health jurisdictions, we will provide systematic data regarding the panoply of programs and policies that have been enacted to support PrEP use. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/80911.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.